Purchase any WEBINAR and get
Validity : 25th Feb'24 to 06th Mar'24
FDA’s sweeping definition of labeling includes what is said or represented, even by images, on a social media platform. If the information can reach a consumer, FDA cares, even if you did not publish the information. Firms need to watch for promotional trespassers making off-label claims. Websites, chat rooms, op-ed articles, or even your own postings on social media can cause your product to be misbranded, i.e., illegal. One big issue is how you patrol and control what someone else is saying about your product in a public forum. Once the off-label information is out there, what is the scope of your responsibility?
Casper (Cap) Uldriks, through his firm “Encore Insight LLC,” brings over 32 years of experience from the FDA. He specialized in the FDA’s medical device program as a field investigator, served as a senior manager in the Office of Compliance and an Associate Center Director for the Center for Devices and Radiological Health. He developed enforcement actions and participated in the implementation of new statutory requirements. His comments are candid, straightforward and of practical value. He understands how FDA thinks, how it operates and where it is headed. Based on his exceptionally broad experience and knowledge, he can synthesize FDA’s domestic and international operational programs, institutional policy and thicket of legal variables into a coherent picture. Professional credentials: JD – Suffolk University, licensed in Massachusetts and the District of Columbia; M.Div in psychology – Boston University with internship through Harvard University.